Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-label Randomized Study of MK-2870 ± Pembrolizumab vs Physician’s Choice in HR+/HER2- Advanced Breast Cancer
jRCT2031240476Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in breast cancer (3 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival (PFS). Started Jan 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031240476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240476.